Effects of arsenic-, platinum- and gold-containing drugs on the disposition of exogenous selenium in rats

Z. Gregus, A. Gyurasics, I. Csanaky

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Having found that the electrophilic model compound sulfobromophthalein markedly altered the fate of exogenous selenium in the body by reacting in vivo with nucleophilic selenium metabolites, the effects of metal-containing drugs with expected selenium reactivity were tested on biliary, urinary, and pulmonary excretion. Tissue distribution of selenium in selenite-injected rats was also examined. Coadministration with [75Se]selenite (10 μmol/kg, iv) of the trypanosomicid arsenicals (100 μmol/kg, iv) trimelarsan (TMA) or melarsoprol (MAP), the antitumor cisplatin (25 μmol/kg, iv), or the antirheumatic gold sodium thiomalate (25 or 50 μmol/kg, iv) significantly altered the disposition of 75Se, whereas carboplatin (100 μmol/kg, iv) did not produce such an effect. The most dramatic alterations included the ~ 20-fold increase in the biliary excretion rate of selenium in response to TMA and MAP, the almost complete cessation of the exhalation of selenium as dimethyl selenide after administration of the arsenic- and gold-containing drugs, and the manifold accumulation of selenium in the blood plasma following gold injection. Direct chemical reaction of the drugs with nucleophilic selenite metabolites in the body may underlie these alterations. The tight coordination in time and extent observed between the biliary excretion of arsenic and selenium in rats receiving either of the arsenicals and selenite supports this hypothesis. However, attempts to detect selenium-containing biliary metabolites of TMA and MAP have failed, possibly owing to their instability. In summary, the arsenic-, platinum- and gold-containing drugs significantly influence the fate of exogenous selenium, whereby they may adversely affect the availability of this essential element for synthesis of selenoenzymes. Furthermore, the capability of TMA and MAP to enhance the biliary and total excretion of selenium renders these drugs significant candidates for antidotes in selenium intoxication.

Original languageEnglish
Pages (from-to)22-31
Number of pages10
JournalToxicological Sciences
Volume57
Issue number1
Publication statusPublished - 2000

Fingerprint

Arsenic
Selenium
Platinum
Gold
Rats
Melarsoprol
Pharmaceutical Preparations
Selenious Acid
Metabolites
Arsenicals
Gold Sodium Thiomalate
Sulfobromophthalein
Exhalation
Antidotes
Carboplatin
Tissue Distribution
Cisplatin
Chemical reactions
Blood
Metals

Keywords

  • Arsenic
  • Biliary excretion
  • Cisplatin
  • Gold
  • Melarsoprol
  • Selenium

ASJC Scopus subject areas

  • Toxicology

Cite this

Effects of arsenic-, platinum- and gold-containing drugs on the disposition of exogenous selenium in rats. / Gregus, Z.; Gyurasics, A.; Csanaky, I.

In: Toxicological Sciences, Vol. 57, No. 1, 2000, p. 22-31.

Research output: Contribution to journalArticle

@article{d3df90ea29574ed99ab12ed133ace31e,
title = "Effects of arsenic-, platinum- and gold-containing drugs on the disposition of exogenous selenium in rats",
abstract = "Having found that the electrophilic model compound sulfobromophthalein markedly altered the fate of exogenous selenium in the body by reacting in vivo with nucleophilic selenium metabolites, the effects of metal-containing drugs with expected selenium reactivity were tested on biliary, urinary, and pulmonary excretion. Tissue distribution of selenium in selenite-injected rats was also examined. Coadministration with [75Se]selenite (10 μmol/kg, iv) of the trypanosomicid arsenicals (100 μmol/kg, iv) trimelarsan (TMA) or melarsoprol (MAP), the antitumor cisplatin (25 μmol/kg, iv), or the antirheumatic gold sodium thiomalate (25 or 50 μmol/kg, iv) significantly altered the disposition of 75Se, whereas carboplatin (100 μmol/kg, iv) did not produce such an effect. The most dramatic alterations included the ~ 20-fold increase in the biliary excretion rate of selenium in response to TMA and MAP, the almost complete cessation of the exhalation of selenium as dimethyl selenide after administration of the arsenic- and gold-containing drugs, and the manifold accumulation of selenium in the blood plasma following gold injection. Direct chemical reaction of the drugs with nucleophilic selenite metabolites in the body may underlie these alterations. The tight coordination in time and extent observed between the biliary excretion of arsenic and selenium in rats receiving either of the arsenicals and selenite supports this hypothesis. However, attempts to detect selenium-containing biliary metabolites of TMA and MAP have failed, possibly owing to their instability. In summary, the arsenic-, platinum- and gold-containing drugs significantly influence the fate of exogenous selenium, whereby they may adversely affect the availability of this essential element for synthesis of selenoenzymes. Furthermore, the capability of TMA and MAP to enhance the biliary and total excretion of selenium renders these drugs significant candidates for antidotes in selenium intoxication.",
keywords = "Arsenic, Biliary excretion, Cisplatin, Gold, Melarsoprol, Selenium",
author = "Z. Gregus and A. Gyurasics and I. Csanaky",
year = "2000",
language = "English",
volume = "57",
pages = "22--31",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Effects of arsenic-, platinum- and gold-containing drugs on the disposition of exogenous selenium in rats

AU - Gregus, Z.

AU - Gyurasics, A.

AU - Csanaky, I.

PY - 2000

Y1 - 2000

N2 - Having found that the electrophilic model compound sulfobromophthalein markedly altered the fate of exogenous selenium in the body by reacting in vivo with nucleophilic selenium metabolites, the effects of metal-containing drugs with expected selenium reactivity were tested on biliary, urinary, and pulmonary excretion. Tissue distribution of selenium in selenite-injected rats was also examined. Coadministration with [75Se]selenite (10 μmol/kg, iv) of the trypanosomicid arsenicals (100 μmol/kg, iv) trimelarsan (TMA) or melarsoprol (MAP), the antitumor cisplatin (25 μmol/kg, iv), or the antirheumatic gold sodium thiomalate (25 or 50 μmol/kg, iv) significantly altered the disposition of 75Se, whereas carboplatin (100 μmol/kg, iv) did not produce such an effect. The most dramatic alterations included the ~ 20-fold increase in the biliary excretion rate of selenium in response to TMA and MAP, the almost complete cessation of the exhalation of selenium as dimethyl selenide after administration of the arsenic- and gold-containing drugs, and the manifold accumulation of selenium in the blood plasma following gold injection. Direct chemical reaction of the drugs with nucleophilic selenite metabolites in the body may underlie these alterations. The tight coordination in time and extent observed between the biliary excretion of arsenic and selenium in rats receiving either of the arsenicals and selenite supports this hypothesis. However, attempts to detect selenium-containing biliary metabolites of TMA and MAP have failed, possibly owing to their instability. In summary, the arsenic-, platinum- and gold-containing drugs significantly influence the fate of exogenous selenium, whereby they may adversely affect the availability of this essential element for synthesis of selenoenzymes. Furthermore, the capability of TMA and MAP to enhance the biliary and total excretion of selenium renders these drugs significant candidates for antidotes in selenium intoxication.

AB - Having found that the electrophilic model compound sulfobromophthalein markedly altered the fate of exogenous selenium in the body by reacting in vivo with nucleophilic selenium metabolites, the effects of metal-containing drugs with expected selenium reactivity were tested on biliary, urinary, and pulmonary excretion. Tissue distribution of selenium in selenite-injected rats was also examined. Coadministration with [75Se]selenite (10 μmol/kg, iv) of the trypanosomicid arsenicals (100 μmol/kg, iv) trimelarsan (TMA) or melarsoprol (MAP), the antitumor cisplatin (25 μmol/kg, iv), or the antirheumatic gold sodium thiomalate (25 or 50 μmol/kg, iv) significantly altered the disposition of 75Se, whereas carboplatin (100 μmol/kg, iv) did not produce such an effect. The most dramatic alterations included the ~ 20-fold increase in the biliary excretion rate of selenium in response to TMA and MAP, the almost complete cessation of the exhalation of selenium as dimethyl selenide after administration of the arsenic- and gold-containing drugs, and the manifold accumulation of selenium in the blood plasma following gold injection. Direct chemical reaction of the drugs with nucleophilic selenite metabolites in the body may underlie these alterations. The tight coordination in time and extent observed between the biliary excretion of arsenic and selenium in rats receiving either of the arsenicals and selenite supports this hypothesis. However, attempts to detect selenium-containing biliary metabolites of TMA and MAP have failed, possibly owing to their instability. In summary, the arsenic-, platinum- and gold-containing drugs significantly influence the fate of exogenous selenium, whereby they may adversely affect the availability of this essential element for synthesis of selenoenzymes. Furthermore, the capability of TMA and MAP to enhance the biliary and total excretion of selenium renders these drugs significant candidates for antidotes in selenium intoxication.

KW - Arsenic

KW - Biliary excretion

KW - Cisplatin

KW - Gold

KW - Melarsoprol

KW - Selenium

UR - http://www.scopus.com/inward/record.url?scp=0033851394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033851394&partnerID=8YFLogxK

M3 - Article

C2 - 10966508

AN - SCOPUS:0033851394

VL - 57

SP - 22

EP - 31

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 1

ER -